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What’s Known on This Subject
Twenty percent of children with congenital toxoplasmosis have retinochoroidal lesions
by school age. Clinicians lack information on which children are most at risk and need
ophthalmic follow-up andwhether prenatal and postnatal treatment reduces the risk of
ocular disease.
What This Study Adds
Prenatal treatment did not signiﬁcantly reduce the risk of retinochoroiditis. Children
with congenital toxoplasmosis who have no retinochoroiditis in early infancy are at low
risk of subsequent lesions and may not justify postnatal treatment and repeated oph-
thalmic assessments.
ABSTRACT
OBJECTIVE.By school age, 20% of children infected with congenital toxoplasmosis will
have 1 retinochoroidal lesion. We determined which children are most at risk and
whether prenatal treatment reduces the risk of retinochoroiditis to help clinicians
decide about treatment and follow-up.
PATIENTS AND METHODS.We prospectively studied a cohort of children with congenital
toxoplasmosis identified by prenatal or neonatal screening in 6 European countries.
We determined the effects of prenatal treatment and prognostic markers soon after
birth on the age at first detection of retinochoroiditis.
RESULTS.Of 281 children with congenital toxoplasmosis, 50 developed ocular disease,
and 17 had recurrent retinochoroiditis during a median follow-up of 4.1 years.
Prenatal treatment had no significant effect on the age at first or subsequent lesions.
Delayed start of postnatal treatment did not increase retinochoroiditis, but the
analysis lacked power. Older gestational age at maternal seroconversion was weakly
associated with a reduced risk of retinochoroiditis. The presence of nonocular clinical
manifestations of congenital toxoplasmosis at birth strongly predicted retinochoroid-
itis. For 92% (230 of 249) of children with no retinochoroiditis detected before 4
months of age, the probability of retinochoroiditis by 4 years was low, whether
clinical manifestations were present or not 8.0%.
CONCLUSIONS. Prenatal treatment did not significantly reduce the risk of retinochoroid-
itis in this European cohort. If children have no retinochoroiditis in early infancy, the
low risk of subsequent ocular disease may not justify postnatal treatment and
repeated ophthalmic assessments during childhood. Controlled trials are needed to
address the lack of evidence for the effectiveness of postnatal treatment.
CONGENITAL TOXOPLASMOSIS CAUSES retinochoroidal lesions, which can occur atany time in fetal or postnatal life. The risk of retinochoroiditis rises from 10% in
infancy to approximately one third by 12 years of age in children whose infection
was identified by screening.1,2 More than 90% of children with retinochoroiditis have
normal vision in their best eye; severe bilateral impairment is rare.2,3
Prevention of retinochoroiditis through prenatal and postnatal antitoxoplasma
treatment is one of the principal rationales for prenatal and neonatal toxoplasma
screening programs operating in Europe, the United States, and South America.4,5 A
recent meta-analysis of all of the available cohort studies of children with congenital
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nochoroiditis in infancy.5 Less is known about the long-
er-term effects of prenatal treatment on retinochoroidi-
tis. One French cohort study found no evidence for any
benefit of timing or the type of prenatal treatment (spi-
ramycin or pyrimethamine-sulfonamide combination)
in children followed to school age, but, because virtually
all of the women were treated, the effect of treatment
versus no treatment could not be examined.2,6
The present study compares long-term ocular out-
comes in children whose mothers were treated with
those not treated during pregnancy. We also provide
prognostic information for clinicians counseling parents
about their child’s risk of developing retinochoroiditis




The original study population consisted of 284 children,
of which 3 did not have any ophthalmologic examina-
tions. Thus, 281 children identified prospectively by uni-
versal prenatal (n  210) or neonatal screening (n  71)
in 6 European countries are included (Table 1). All ex-
cept 25 of the children enrolled in the Danish Neonatal
Screening Study from 1992 to 19967 were part of the
European Multicenter Study on Congenital Toxoplas-
mosis for which screening and treatment programs and
methods for excluding referred infants have been
described in detail elsewhere.1,8
Congenital Infection Status and Ophthalmic Outcomes
Classification of congenital infection was based on sero-
logic follow-up to 1 year, as described previously.8
Ophthalmic examinations were performed after pupil
dilatation a median of 2 times during infancy (1–6 ex-
aminations) and thereafter annually. Ophthalmologists
completed a standard proforma and were asked to use
indirect ophthalmoscopy whenever possible. Laterality
(right or left), site (posterior pole or periphery), size, and
date each retinochoroidal lesion was first detected were
recorded. We defined a recurrence as a new lesion that
was detected for the first time 1 week after a previous
adequate visualization of the retina. At a single exami-
nation, 1 lesion could be detected in the same eye
(termed “multiple lesions”).
Determinants of Age at Retinochoroiditis
Gestational Age at Maternal Seroconversion
The gestational age at maternal seroconversion is a sur-
rogate marker for the timing of fetal infection.8 This
variable was included in all of the analyses, because
we reasoned that the risk of retinochoroiditis might
decrease as fetal immunity matures, a hypothesis sup-
ported by a strong inverse association between
intracranial lesions and gestational age at maternal se-
roconversion.1,5 We imputed the date of maternal
seroconversion as either the midpoint between the last
negative and first positive maternal immunoglobulin M
(IgM) tests for women who had prenatal screening and
a positive IgG test at the first IgM test or 14 days before
the first positive IgM test for women with a negative IgG
test at their first positive prenatal IgM test.1,5,9
For children identified by neonatal screening, we
used the dates of the first prenatal booking blood sample
and birth to define the seroconversion interval and im-
puted the date of seroconversion using a regression
analysis with covariates for IgM status (based on the
immunosorbent agglutination assay test and, if not
available, the enzyme-linked immunosorbent assay test)
and the rank of the IgG titer (based on the Dye test and,
if not available, an enzyme-linked immunosorbent assay
test) in the child’s first postnatal sample.5 The multiple
linear regression model was derived from children iden-
tified by prenatal screening and then used to impute the
gestational age at maternal seroconversion for children
identified by neonatal screening. The regression model
was as follows: gestational age at seroconversion in
weeks  33.31272  5.65140 * first IgM test (positive/
equivalent  1, negative  0)  0.32782 * IgG titer per-
centile rank 0.00218 * IgG titer percentile rank squared.
Gestational age at seroconversion was weighted in all of
the analyses by the reciprocal of the interval between the
last negative and first positive test dates or conception and
birth if no prenatal tests were performed. Using this
method, results for the effect of gestational age at maternal
seroconversion on the risk of ocular lesions by 4 years of
age (odds ratio [OR]: 0.97; 95% confidence interval [CI]:
0.93–1.00) agreed closely with previous findings for ocular
lesions during infancy using the maximum likelihood
method in analyses of the same data set (OR: 0.97; 95%CI:
0.94–1.01) and in an individual patient data meta-analysis
















France 171 3.8 (0.0–7.1) 26 (15) 10 3 2
Austria/Italy 39 4.4 (0.0–7.5) 8 (21) 4 1 0
Neonatal screening
Poland/Scandinavia 71 4.2 (0.1–11.5) 16 (22) 7 3 2
Total 281 4.1 (0.0–11.5) 50 (18) 21 (42%) 7 (14%) 4 (8%)
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of all of the available cohort data sets (OR: 0.97; 95% CI:
0.93–1.00).1,5
Treatment
Prenatal testing and treatment regimens varied. France
used monthly retesting of susceptible women and spira-
mycin as the first treatment, whereas Austria used
3-monthly retesting and a pyrimethamine-sulfonamide
combination as the first treatment (details reported else-
where).8 Mothers were not treated in neonatal screening
centers.
To determine the association between the timing of
prenatal treatment and age at detection of retinocho-
roiditis, we compared prenatal treatment started before
4 weeks or4 weeks after maternal seroconversion with
no prenatal treatment (4 weeks is close to the median
treatment delay for women in France).1 We also exam-
ined the effect of any treatment compared with none
and differences in effects among the types of prenatal
treatment.
Only limited investigation of the effect of postnatal
treatment was possible, because all except 3 of the chil-
dren received postnatal treatment, all with regimens
containing pyrimethamine-sulfonamide. Protocols for
the duration of treatment varied from 3 months in Den-
mark to 24 months in parts of France.1 Because postnatal
treatment can only have an effect if given before retino-
choroiditis occurs, we restricted these analyses to chil-
dren who had a normal ophthalmoscopy after birth.
Clinical Prognostic Markers
Clinicians need to counsel parents about their child’s
prognosis to make decisions about postnatal treatment
and follow-up. We analyzed the effect of demographic
variables (maternal age, child’s gender, and region de-
fined as France, Scandinavia and Poland, and Austria or
Italy), clinical markers in pregnancy (fetal ultrasound
results or maternal lymphadenopathy), and clinical
manifestations present at or soon after birth (before 4
months old) on the age at first detection of retinocho-
roiditis. Four months was chosen because virtually all of
the initial clinical assessments had been completed by
this time. Clinical manifestations in the child were
defined in a mutually exclusive hierarchy as follows:
serious neurologic findings (seizure, hydrocephaly, or
microcephaly); intracranial lesions detected by postnatal
ultrasound scan (ventricular dilatation and/or intracra-
nial calcification without serious neurologic findings);
lymphadenopathy or hepatosplenomegaly; and no man-
ifestations. The cohort ascertained in Denmark between
1992 and 1996 lacked data on non-ocular clinical man-
ifestations and timing of postnatal treatment and was
excluded from these analyses.7
Analyses
Descriptive statistics include relative frequencies and
percentages for categorical variables. Kaplan-Meier
models were fitted to describe the time to first detection
of a lesion after birth. If a child had no lesions, censoring
occurred at the date of the last ophthalmic examination.
The primary analysis used birth as the point after
which lesions could be detected (time 0). We compared
the effect of prenatal and postnatal determinants on the
age at detection of first retinochoroidal lesion using the
log-rank test and derived hazard ratios, adjusted for
gestational age at maternal seroconversion using Cox
proportional hazards regression. The probability of reti-
nochoroiditis and 95% CIs were estimated from the
unadjusted survival analyses using 1 minus the estimate
of success from the time of the last previous event and
corresponding SE. To compare the effect of determinants
on the timing and occurrence of recurrent lesions we
used the Prentice, Williams, and Peterson total time
model for ordered multiple failure times with common
effects,10 which assumes proportional hazards with time-
dependent strata for times to each of the ordered k
events. A common-effects model was chosen because of
limited power (ie, few subjects with 3 or 4 events). All of
the multivariate analyses were adjusted for gestational
age at maternal seroconversion and weighted by the
reciprocal of the interval between the last negative and
first positive test dates or birth. Baseline characteristics of
those lost to follow-up by 1 year were compared with
those with data at 1 year using 2 or exact tests for
categorical variables and t tests or Wilcoxon rank-sum
tests as appropriate for continuous variables. Results
were considered statistically significant for P  .05.
We used sensitivity analyses, with time 0 redefined as
the gestational age at maternal seroconversion, to take
into account the fact that infants infected early in preg-
nancy might develop retinochoroiditis sooner after birth
than infants infected in later pregnancy. We also exam-
ined the effect of prenatal treatment on retinochoroiditis
that occurred for the first time after birth by restricting
the analysis to children whose first ophthalmoscopy af-
ter birth was normal. To test for possible bias, all of the
analyses were repeated for French centers only, because
referral bias is expected to be low in France, where
compliance with screening is mandated by law.11 All of
the calculations were performed using SAS 9.1.2 (SAS
Institute, Inc, Cary, NC).
RESULTS
Study Population
The cohort was composed of 284 children with congen-
ital toxoplasmosis. All except 3 of the children had 1
ophthalmoscopy examination during a median fol-
low-up of 4.1 years (Table 1). Indirect ophthalmoscopy
was used at least once in all of the children and for
nearly two thirds (180 of 281 [64%]) of the latest ex-
aminations. There was no significant association (P 
.05) between clinical characteristics and whether (n 
15) or not (n  163) the child was lost to follow-up at 1
year.
Forty-nine children had 1 retinochoroidal lesion,
and in 1 additional child with microphthalmia, cataracts,
and vitreous opacities, we assumed that retinochoroiditis
was present at birth, although the retina could not be
visualized (50 of 281 [18%]). Less than half of the
children with retinochoroiditis (21 of 50 [42%]) had 1
recurrent lesion, and 4 (8%) had 3 recurrences (Table
PEDIATRICS Volume 121, Number 5, May 2008 e1217
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TABLE 2 Hazard Ratios for Age at First Detection of Retinochoroiditis and Probability of Retinochoroiditis by 4 Years Old According to
Pregnancy and Infant Characteristics
Characteristic No. of Children With Hazard Ratio
(95% CI)a
Probability of Retinochoroiditis
by 4 Years (95% CI), %
Retinochoroiditis Congenital
Toxoplasmosis
All children 50 281 — 16.5 (11.9–21.1)
Maternal factors
Gestational age at seroconversion: per week
increase in gestation
50 281 0.97 (0.93–1.00) —
Early versus late pregnancy
20 wk (reference) 38 234 1.0 14.6 (12.4–19.4)
20 wk 12 47 2.10 (1.08–4.10)b 25.8 (12.4–39.3)
Lymphadenopathy during pregnancyc
None (reference) 38 243 1.0 16.0 (11.0–20.9)
Any 3 13 1.19 (0.32–4.46) 29.5 (0.0–59.6)
Mother’s age
Per year increase in age 50 281 0.99 (0.93–1.05) —
Maternal age groups
30 y (reference) 33 190 1.0 16.5 (10.8–22.2)
30 y 17 91 0.98 (0.54–1.78) 16.3 (8.4–24.2)
Region of study
France (reference) 26 171 1.0 16.2 (10.1–22.3)
Italy/Austria 8 39 1.11 (0.45–2.74) 18.9 (6.2–31.4)
Scandinavia/Poland 16 71 0.76 (0.29–1.98) 16.0 (7.3–24.8)
Prenatal treatment
Treated versus untreated
Untreated (reference) 20 103 1.0 15.5 (8.2–22.7)
Treated during pregnancy 30 178 0.83 (0.39–1.79) 17.1 (11.1–23.1)
Treatment delay (treated women only)
Per week of delay 30 169 0.99 (0.87–1.12) —
Treatment delay (versus no treatment)
No treatment (reference) 20 103 1.0 15.5 (8.2–22.7)
4 wk 18 114 0.82 (0.38–1.79) 15.6 (8.4–22.7)
4 wk 12 64 0.84 (0.32–2.20) 19.7 (9.0–30.3)
Type of treatment
No treatment (reference) 20 103 1.0 15.5 (8.2–22.7)
Spiramycin alone 9 82 0.50 (0.20–1.23) 13.1 (4.9–21.2)
Spiramycin and then P&S 16 58 1.52 (0.67–3.46) 27.3 (14.8–39.8)
P&S 5 38 0.55 (0.17–1.78) 11.2 (0.8–21.6)
Prenatal and postnatal treatmentc
Delay to start of prenatal/postnatal treatment
Per week of delay 41 256 1.00 (0.99–1.01) —
Age at start of postnatal treatmentd
Per week of postnatal age 21 218 1.00 (0.99–1.01) —
Clinical characteristics of fetus/child
Gender of child
Male (reference) 28 152 1.0 15.2 (9.3–21.0)
Female 22 129 1.11 (0.62–1.97) 18.0 (10.7–25.2)
Gestation at birth 50 281 0.95 (0.82–1.10) —
Term (reference) 41 243 1.0 15.9 (11.0–20.8)
Preterm 9 38 0.98 (0.42–2.31) 18.7 (6.2–31.3)
Fetal ultrasound scan (US)e
Any abnormality
Normal scan (reference) 29 198 1.0 15.0 (9.6–20.5)
Any abnormality 5 9 6.60 (2.06–21.09)b 55.6 (23.1–88.0)
Intracranial calciﬁcation/ventricular dilatation
No intracranial abnormality (reference) 29 202 1.0 14.8 (9.4–20.1)
Intracranial abnormality 5 5 118.29 (21.62–647.22)b 1.0 (47.8–1.0)
Clinical manifestations in early infancy (exclusive
hierarchy before 4 mo)c
Speciﬁc manifestations
None (reference) 26 221 1.0 11.8 (7.2–16.4)
Lymphadenopathy/hepatosplenomegaly 2 6 4.84 (1.19–19.67)b 44.4 (0.0–93.1)
e1218 FREEMAN et al
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1). The shortest interval between a negative examina-
tion and a new lesion was 22 days. Twenty children (20
of 281 [7%]) had retinochoroiditis detected at their first
ophthalmoscopy: 20 of 50 (40%) children who eventu-
ally developed retinochoroiditis had lesions detected at
their first postnatal ophthalmoscopy.
Mothers of 103 children received no prenatal treat-
ment, of whom 32 were identified as infected by prena-
tal screening. Failure to treat these women is probably
because they were identified late in pregnancy (median
age at first positive test: 38.6 weeks; interquartile range
[IQR]: 37.4–40.0 weeks).5,8 The median age at the start
of postnatal treatment was 3 days (IQR: 0–15 days) in
prenatal centers and 27 days (IQR: 23–34 days) in Eu-
ropean neonatal centers.
Determinants of Age at First Retinochoroidal Lesion
The probability of developing retinochoroiditis by 4
years old was 16% (Table 2). Two prenatal characteris-
tics were statistically significantly associated with the
risk of retinochoroiditis (Table 2). Fetal ultrasound ab-
normalities markedly increased the risk of retino-
choroiditis, and all 5 of the children with intracranial
abnormalities on fetal ultrasound developed retinocho-
roiditis. Secondly, there was a weak, but not statistically
significant, association between increasing gestational
age at maternal seroconversion and a decreased risk of
retinochoroiditis. Children whose mothers serocon-
verted in the first half of pregnancy compared with the
second half were twice as likely to develop retinocho-
roiditis (Fig 1). We found no significant effect of prenatal
treatment compared with no treatment or of the timing
or type of prenatal treatment on age at first detection of
retinochoroiditis (Table 2). This finding is illustrated by
the similarity of estimated survivor functions for France,
Austria, and Italy and the neonatal screening centers in
Scandinavia and Poland (Fig 2). There was no evidence
that prenatal treatment significantly reduced the risk of
recurrent lesions after birth: the hazard ratio for age at
the first or recurrent lesion in children given any treat-
ment compared with none was 1.01 (95% CI: 0.55–
1.86).
The timing of prenatal or postnatal treatment, or just
of postnatal treatment, was not associated with age at
first detection of retinochoroiditis (Table 2). A total of 15
of 50 children (18 of 64 lesion occurrences) had lesions
detected while receiving postnatal treatment for be-
tween 2 and 64 weeks.
FIGURE 1
Survival analysis showing age at ﬁrst detection of toxoplasmic ret-
inochoroiditis according to maternal seroconversion before or af-
ter 20 weeks’ gestation.
TABLE 2 Continued
Characteristic No. of Children With Hazard Ratio
(95% CI)a
Probability of Retinochoroiditis
by 4 Years (95% CI), %
Retinochoroiditis Congenital
Toxoplasmosis
Postnatal cranial US abnormal 9 24 2.49 (1.01–6.13)b 39.4 (19.0–59.8)
Serious neurologic sequelae 4 5 43.31 (10.33–181.55)b 80.0 (44.9–100)
Any clinical manifestation
None (reference) 26 221 1.0 11.8 (7.2–16.4)
Any 15 35 3.65 (1.79–7.46)b 46.2 (28.4–64.0)
a Data were adjusted for gestational age at maternal seroconversion.
b Hazard ratios show an effect that is statistically signiﬁcant at the 5% level.
c European Multicentre Study on Congenital Toxoplasmosis cohort (n 256) is used as data not collected in the Denmark 1992–1996 cohort (n 25).
d Data show children in European Multicentre Study on Congenital Toxoplasmosis centers who had no retinochoroiditis on their ﬁrst postnatal ophthalmoscopy examination before starting
postnatal treatment (n 218; ie, 38 excluded, either because of a lesion before 4 months or no examination before 4 months and a ﬁrst examination with a lesion thereafter). These analyses
determine the effect of treatment on lesions that occur for the ﬁrst time after birth.
e Data show mothers in prenatal screening centers (n 210, 3 with missing data on fetal ultrasound result). Five had intracranial lesions on fetal ultrasound 3 ventricular dilatation, and 2 with
intracranial calciﬁcation. Earliest abnormality was identiﬁed at 22.7 weeks of gestation.
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Clinical Manifestations
Children with nonocular manifestations of congenital
toxoplasmosis detected before 4 months of age more
than doubled their risk of having retinochoroiditis de-
tected at birth or later in childhood compared with chil-
dren with no manifestations (Table 2). The risk of a first
lesion by 4 years of age was highest for children with
serious neurologic sequelae (80%) but was also signifi-
cantly increased for children with intracranial lesions
but no serious neurologic impairment (39%) and for
those just with lymphadenopathy or hepatosplenomeg-
aly (44%) compared with children with no clinical man-
ifestations (12%; Table 2).
Initial ophthalmoscopy findings, results of intracra-
nial imaging, and the clinical examination would be
available to clinicians when they counsel parents about
their child’s prognosis in early infancy (defined as before
4 months of age). Nearly half of the children who even-
tually developed retinochoroiditis had already had their
first lesion detected before 4 months of age (22 of 50
[44%]), as had 80% of the children with clinical mani-
festations (12 of 15). Children without retinochoroiditis
detected by 4 months had a low risk of developing
retinochoroiditis by 4 years (Table 3 and Fig 3), which
was similar for children with and without other clinical
manifestations (hazard ratio for clinical manifestations
in children with no manifestations, group 1, versus those
with nonocular manifestations only: 0.92; 95% CI:
0.18–4.56). The risk of recurrent retinochoroiditis in
children with lesions detected before 4 months (groups 3
and 4; Table 3 and Fig 3) was high, but because of the
small number of events, the CIs were wide.
Results for the effect of prognostic markers on the age
at first and recurrent lesions were similar to those for the
age at first lesion only (Table 2), but CIs were wider.
None of the hazard ratios changed appreciably in sensi-
tivity analyses restricted to French centers or to infants
who had a first negative examination after birth or if
time 0 was taken as the gestational age at seroconversion
rather than birth (results not shown).
DISCUSSION
We found no evidence that prenatal treatment signifi-
cantly reduced the risk of retinochoroiditis in children
with congenital toxoplasmosis followed up to 4 years of
age. The main determinants of retinochoroiditis were an
abnormal fetal ultrasound showing intracranial abnor-
malities and the presence of intracranial or systemic
clinical manifestations of congenital toxoplasmosis in
early infancy. Children with no retinochoroidal lesions
detected in early infancy had a low risk of subsequent
ocular disease, regardless of the presence of other clinical
manifestations. The gestational age at maternal serocon-
version had a weak effect on the risk of retinochoroiditis
by 4 years.
Our results are based on the largest multicenter study
of children with congenital toxoplasmosis and are sup-
ported by results from an earlier single-center cohort of
327 infected children in Lyon, France, with a median
follow-up of 6 years (79 children had retinochoroidi-
TABLE 3 Risk of Retinochoroiditis According to Clinical Manifestations Detected Before 4 Months Postnatal Age
Prognostic Group Manifestations Before 4 mo No. of Children With Newly
Detected Retinochoroiditis
Between 4 mo and 4 y








1. No manifestations No No 17 208 (83.5) 8.0 (4.0–12.1)
2. No retinochoroiditis No Yes 3 22 (8.8) 17.9 (0.0–36.5)
3. Retinochoroiditis Yes No 3 8 (3.2) 30.0 (0.0–65.7)
4. Both Yes Yes 8 11 (4.4) 69.7 (31.1–98.3)
a The denominator excludes 25 children in the Danish cohort 1992–1996 and 7 children without follow-up beyond 4 months of age (ie, 281 32 249).
b Data were estimated from survival analyses.
FIGURE 2
Survival analysis age at ﬁrst detection of toxoplasmic retinocho-
roiditis according to the region of study and type of screening.
Prenatal screening results with monthly retesting in France, every
3months in Italy or Austria, and neonatal screening in Poland and
Scandinavia.
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tis).2,6 In the Lyon cohort, the risk of retinochoroiditis by
4 years (18%) was very close to our result (16%), and
similarly weak, nonsignificant associations were found
for gestational age at maternal seroconversion and pre-
natal treatment.6 Our study maximized the power to
detect an effect of prenatal treatment by virtue of its
sample size, length of follow-up, and the large propor-
tion of untreated mothers. Longer follow-up would in-
crease the power to detect a treatment effect but may
selectively favor children with retinochoroiditis, who are
more likely to comply with follow-up, thereby overesti-
mating the risk of disease.
Findings from previous cohort studies are consistent
with our results showing no statistically significant effect
of prenatal treatment on retinochoroiditis, even when
treatment is given soon after maternal seroconver-
sion.1,5,12 These findings challenge the rationale for pre-
natal screening to offer prenatal treatment to prevent
ocular disease.
The effect of postnatal treatment has not been addressed
by any concurrent comparative studies.13 In the present
study, we examined the effect of delayed starting of post-
natal treatment and found no evidence of harm, although
the power to detect an effect was limited, because there
was little variation in the age at the start of postnatal
treatment. We hypothesize that any effect of postnatal
treatment is likely to be less than for prenatal treatment,
because treatment is likely to be most effective when given
soon after maternal seroconversion, before the parasite
forms bradyzoite cysts that are impenetrable to antibiotics.
Evidence is also lacking about whether postnatal treatment
has any effect on recurrent lesions, except for patients with
frequent recurrences in Brazil where the Toxoplasma gondii
genotype is associated with more severe disease.14 Doubts
about the benefits of postnatal treatment are exemplified
by varying practice. In a Dutch cohort study, pediatricians
could not be persuaded to treat infected infants at all,13 and
in the Danish National Screening Program, treatment was
given for just 3 months. The Danish screening program,
which started in 1992, was stopped in August 2007 be-
cause of the low burden of disease and a lack of evidence
that treatment is effective (E. Petersen, written communi-
cation, 2007).5 The long-standing practice of treating for 1
year, or in some centers, 2 years after birth1 has no defen-
sible evidence base and presents a considerable burden for
the child and family, as well as risk of adverse effects
requiring stopping treatment ranging from 14% to 58%.15
Evidence is needed of the effectiveness of repeated
routine ophthalmic examinations throughout childhood
for children with normal ophthalmoscopy in early in-
fancy who have a low risk of retinochoroiditis. Instead,
clinicians could advise parents to bring the child for
assessment should ocular signs or symptoms develop
and ensure that routine school vision screening is un-
dertaken at 3 to 4 years old. In the Danish study, oph-
thalmologists could not be persuaded of the benefits of
annual ophthalmoscopy examinations (E. Petersen, ver-
bal communication, 2004), whereas in some centers
examinations are repeated at 6 monthly intervals. We
reported previously that at 3 to 4 years, infected and
uninfected children born to toxoplasma-infected moth-
ers had no detectable differences in a range of develop-
mental outcomes, but parents of infected children were
significantly more anxious.16 Part of this anxiety may be
attributable to concerns about vision loss in their child, a
fear that is reinforced by repeated examinations.
Implications for Follow-up
Currently, all children with congenital toxoplasmosis
identified by prenatal or neonatal screening are treated
postnatally and followed up throughout childhood. Our
results provide an evidence base for an alternative strat-
egy in which postnatal treatment and routine follow-up
is offered according to prognosis, taking into account the
lack of evidence for a significant effect of postnatal treat-
ment (Table 3). We suggest that 91% (20 of 230) of
infected children who are at lower risk of retinochoroid-
itis (groups 1 and 2) could be offered a short course or no
postnatal treatment. Instead of routine annual ophthal-
mic examinations, parents could request an assessment
if the child develops ocular symptoms or signs. Routine
ophthalmic follow-up is likely to be most important for
children with early clinical manifestations and/or reti-
nochoroiditis (groups 3 and 4), who have a high risk of
FIGURE 3
Survival analysis showing age at detection of toxoplasmic retino-
choroiditis occurring at or after 4 months of age according to the
presence of eye and clinical manifestations before 4 months of
age.
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recurrent lesions and compose 5% (12 of 256) of all
infected infants. Although generalizable to regions in
which T gondii type 2 strain predominates (Europe and
North America), these findings may not apply to areas
with more virulent strains, most notably central and
South America.17,18
CONCLUSION
In this European cohort we found no evidence that
prenatal treatment statistically significantly reduced the
risk of retinochoroiditis. Although the analysis of post-
natal treatment lacked power, it seems unlikely that
postnatal treatment would be more effective than pre-
natal treatment for retinochoroiditis. Given these find-
ings and the low risk of retinochoroiditis in 90% of
children with congenital toxoplasmosis, clinicians need
to reconsider their practice of repeated ophthalmoscopy
throughout childhood combined with postnatal treat-
ment during infancy. An alternative approach might be
to confine treatment and follow-up to the minority of
children with early clinical manifestations and ocular
disease who are most at risk of new ocular lesions post-
natally. For the remainder, the effectiveness of postnatal
treatment and follow-up should be evaluated in a ran-
domized, controlled clinical trial.
ACKNOWLEDGMENTS
This research was part of the European multicenter study
on congenital toxoplasmosis, funded by the European
Commission (BIOMED II No. BMH4-CT98-3927 and
QLG5-CT-2000-00846). Additional support has been pro-
vided by the National Eye Institute, grant R03 EY015287-
01. Research at the Institute of Child Health and Great
Ormond Street Hospital for Children National Health Ser-
vice Trust benefits from research and development funding
received from the National Health Service Executive.
We acknowledge the contributions of the members of
the European Multicentre Study on Congenital Toxo-
plasmosis (EMSCOT). Members of the writing commit-
tee include: RE Gilbert (chair), K Freeman, K Tan, A
Prusa, E Petersen, W. Buffolano, G Malm, M Cortina-
Borja. The following centers contributed data to this
report (number of patients contributed): A Prusa, M
Hayde, A Pollak (24; University Children’s Hospital, Vi-
enna), M Wallon, F Peyron (44; Hoˆpital de la Croix
Rousse, Lyon), S. Romand, P Thulliez (65; Institut de
Puericulture, Paris), W Buffolano, A. Romano (11; Uni-
versita di Napoli, Naples), J Franck, H Dumon (20; Hoˆ-
pital de la Timone, Marseille), P Bastien, E Issert, M-H
Bessieres (20; Hoˆpital de Rangueil, Toulouse), N Ferret,
P Marty (8; Hoˆpital de l’Archet, Nice), C Chemla, (8;
Hoˆpital Maison Blanche, Reims), H Pelloux, H Fricker-
Hidalgo, C Bost-Bru (6; Centre Hospitalier Universitaire
de Grenoble), E Semprini, V Savasi (4; Milan), M Paul
(29; University Medical Sciences, Poznan), G Malm, B
Evengard (3; Huddinge Hospital, Stockholm), E Pe-
tersen, D Schmidt (39; Statenseruminstitut, Copenha-
gen). RE Gilbert (Principal Investigator), HK Tan, K
Freeman, A Salt, and MR Stanford (Institute of Child
Health, London) were responsible for study design and
coordination. Statistical analysis was conducted by HK
Tan and K Freeman (Institute of Child Health, London).
REFERENCES
1. Gras L, Wallon M, Pollak A, et al. Association between prenatal
treatment and clinical manifestations of congenital toxoplas-
mosis in infancy: a cohort study in 13 European centers. Acta
Paediatr. 2005;94(12):1–12
2. Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular
prognosis in 327 children with congenital toxoplasmosis. Pedi-
atrics. 2004;113(6):1567–1572
3. Tan HK, Schmidt D, Stanford MR, et al. Risk of visual impair-
ment in children with congenital toxoplasmic retinochoroidi-
tis. Am J Ophthalmol. 2007;144(5):648–653
4. Gilbert R, Dezateux C. Newborn screening for congenital
toxoplasmosis: feasible, but benefits are not established. Arch
Dis Child. 2006;91(8):629–631
5. SYROCOT (Systematic Review on Congenital Toxoplasmosis)
study group, Thie´baut R, Leproust S, Cheˆne G, Gilbert R.
Effectiveness of prenatal treatment for congenital
toxoplasmosis: a meta-analysis of individual patients’ data.
Lancet. 2007;369(9556):115–122
6. Binquet C, Wallon M, Quantin C, et al. Prognostic factors for
the long-term development of ocular lesions in 327 children
with congenital toxoplasmosis. Epidemiol Infect. 2003;131(3):
1157–1168
7. Lebech M, Andersen O, Christensen NC, et al. Feasibility of
neonatal screening for toxoplasma infection in the absence of
prenatal treatment. Lancet. 1999;353(9167):1834–1837
8. Gilbert R, Gras L. Effect of timing and type of treatment on the
risk of mother to child transmission of Toxoplasma gondii.
BJOG. 2003;110(2):112–120
9. Thalib L, Gras L, Romand S, et al. Prediction of congenital
toxoplasmosis by polymerase chain reaction analysis of amni-
otic fluid. BJOG. 2005;112(5):567–574
10. Therneau TM, Grambsch PM. Multiple Events Per Subject. Mod-
eling Survival Data: Extending the Cox Model. New York, NY:
Springer-Verlag; 2000:169–194
11. Thulliez P. Screening programme for congenital toxoplasmosis
in France. Scand J Infect Dis. 1992;84(suppl):43–45
12. Gras L, Gilbert RE, Ades AE, Dunn DT. Effect of prenatal
treatment on the risk of intracranial and ocular lesions in
children with congenital toxoplasmosis. Int J Epidemiol. 2001;
30(6):1309–1330
13. Gilbert R, Dunn D, Wallon M, et al. Ecological comparison of
the risks of mother-to-child transmission and clinical manifes-
tations of congenital toxoplasmosis according to prenatal treat-
ment protocol. Epidemiol Infect. 2001;127(1):113–120
14. Gilbert RE, Harden M, Stanford MR. Antibiotics versus control
for toxoplasma retinochoroiditis. Cochrane Database Syst Rev.
2002;(1)
15. Daveluy A, Haramburu F, Bricout H, et al. Review of Data Related
to Side Effects of Drugs Used in Congenital Toxoplasmosis. Bordeaux,
France: EUROTOXO A European Consensus on the State of the
Science; 2005
16. Freeman K, Salt A, Prusa A, et al. Association between con-
genital toxoplasmosis and parent-reported developmental out-
comes, concerns and impairments, in 3 year old children. BMC
Pediatr. 2005;5:23
17. Lehmann T, Marcet PL, Graham DH, Dahl ER, Dubey JP.
Globalization and the population structure of Toxoplasma gon-
dii. Proc Natl Acad Sci U S A. 2006;103(30):11423–11428
18. Ajzenberg D, Banuls AL, Su C, et al. Genetic diversity, clonality
and sexuality in Toxoplasma gondii. Int J Parasitol. 2004;
34(10):1185–1196
e1222 FREEMAN et al
 by on May 15, 2009 www.pediatrics.orgDownloaded from 
DOI: 10.1542/peds.2007-2169 
 2008;121;e1215-e1222; originally published online Apr 21, 2008; Pediatrics
Multicentre Study on Congenital Toxoplasmosis 
Buffolano, Gunilla Malm, Mario Cortina-Borja, Ruth Gilbert and for the European 
Katherine Freeman, Hooi Kuan Tan, Andrea Prusa, Eskild Petersen, Wilma
 European, Prospective Cohort Study








This article cites 15 articles, 4 of which you can access for free
 Subspecialty Collections
 http://www.pediatrics.org/cgi/collection/infectious_disease
 Infectious Disease & Immunity
following collection(s): 
This article, along with others on similar topics, appears in the
 Permissions & Licensing
 http://www.pediatrics.org/misc/Permissions.shtml
tables) or in its entirety can be found online at: 
Information about reproducing this article in parts (figures,
 Reprints
 http://www.pediatrics.org/misc/reprints.shtml
Information about ordering reprints can be found online: 
 by on May 15, 2009 www.pediatrics.orgDownloaded from 
